PODXL and cancer: For PDAC patients with membranous PODXL expression by the polyclonal antibody, cancer-specific survival (CSS) was significantly worse (p = 0.006, Log-rank test); five-year CSS was 14.0% (95% CI 5.2–22.8%) for patients with membranous PODXL expression compared to 24.8% (95% CI 15.0–34.6%) for those with non-membranous expression (Fig 3).